These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37385752)

  • 1. AR activates YAP/TAZ differentially in prostate cancer.
    Salem O; Jia S; Qian BZ; Hansen CG
    Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37385752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo Pathway in Prostate Cancer.
    Salem O; Hansen CG
    Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
    Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
    Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
    EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
    Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
    Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
    Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of stem cell renewal and fate by YAP and TAZ.
    Driskill JH; Pan D
    Nat Rev Mol Cell Biol; 2023 Dec; 24(12):895-911. PubMed ID: 37626124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
    Cao X; Zhao B
    Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of SLC22A3 by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer.
    Seo E; Jee B; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Kang M
    FEBS J; 2023 Mar; 290(6):1645-1662. PubMed ID: 36254631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
    Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
    Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
    Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
    EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into recent findings and clinical application of YAP and TAZ in cancer.
    Franklin JM; Wu Z; Guan KL
    Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the ambivalent role of YAP/TAZ in human cancers.
    Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
    J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined control of the fibroblast contractile program by YAP and TAZ.
    Link PA; Choi KM; Diaz Espinosa AM; Jones DL; Gao AY; Haak AJ; Tschumperlin DJ
    Am J Physiol Lung Cell Mol Physiol; 2022 Jan; 322(1):L23-L32. PubMed ID: 34755530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.